The clinical development and regulatory approval of bedaquiline, delamanid and
pretomanid over the last decade brought about significant progress in the management of …

Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

BACKGROUND: Optimal drug dosing is important to ensure adequate response to
treatment, prevent development of drug resistance and reduce drug toxicity. The aim of …

Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary
global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro …

Bacterial resistance against antibiotics is an emergent medical issue. The development of
novel therapeutic approaches is urgently needed and, in this context, bacteriophages …

Background and aim Tuberculosis (TB) is associated with a high mortality in the intensive
care unit (ICU), especially in subjects with Acute Respiratory Distress Syndrome (ARDS) …

Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and
millions of deaths each year. Around 10% of these cases are in children, but only a fraction …

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and
treatment interruption. The aim of these clinical standards is to encourage best practise for …

Background Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis
and leads to serious complications if left untreated. Some strains of Mycobacterium …

Multidrug-resistant (MDR) tuberculosis (TB) has been emerging at an alarming rate over the
last few years. It has been estimated that about 3% of all pediatric TB is MDR, meaning …